Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

61.74
+0.40000.65%
Post-market: 61.740.00000.00%19:05 EDT
Volume:628.86K
Turnover:38.70M
Market Cap:3.90B
PE:-14.23
High:61.96
Open:61.11
Low:60.93
Close:61.34
Loading ...

Rhythm Pharmaceuticals Inc - Primary Endpoint Achieved With -16.5% Mean Bmi Reduction

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Inc - Setmelanotide Therapy Achieves -16.5% Mean Bmi Change in Patients

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction in Patients (N=120) With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals Inc - Setmelanotide Achieves -19.2% Placebo-Adjusted Bmi Reduction in Adults

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals to Announce Topline Results From Pivotal Phase 3 Transcend Trial Evaluating Setmelanotide in Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
07 Apr

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

GlobeNewswire
·
07 Apr

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com
·
01 Apr

Rhythm Pharmaceuticals Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Mar

Rhythm Pharmaceuticals Regains Licensing Rights to Imcivree Obesity Drug

MT Newswires Live
·
21 Mar

Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?

Insider Monkey
·
21 Mar

BRIEF-Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Reuters
·
21 Mar

Rhythm Pharmaceuticals reacquires rights to Imcivree in China for $6.3M

TIPRANKS
·
21 Mar

Rhythm Pharmaceuticals Inc - Under Agreement, Co to Repay $6.3 Million to Rarestone

THOMSON REUTERS
·
21 Mar

Rhythm Pharmaceuticals Reacquires Licensing Rights to Imcivree® (Setmelanotide) in China With Termination of Agreement With Rarestone Ltd.

THOMSON REUTERS
·
21 Mar

Rhythm Pharmaceuticals- to Return All Rarestone Shares Acquired Under Original Agreement for No Additional Consideration

THOMSON REUTERS
·
21 Mar

BRIEF-Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan

Reuters
·
20 Mar

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

THOMSON REUTERS
·
20 Mar

Rhythm Pharmaceuticals:Setmelanotide in Global Phase 3 Trial for Acquired Hypothalamic Obesity, With Topline Data on Track to Be Disclosed in Q2 2025

THOMSON REUTERS
·
20 Mar

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

GlobeNewswire
·
20 Mar

Citizens JMP pharmaceuticals analysts hold analyst/industry conference call

TIPRANKS
·
19 Mar